Logo
Login
$SYRE
$99.05 +$0.00 (0.0%) After hours

Company Executives

$SYRE Management Team

Dr. Cameron Turtle

Chief Executive Officer

Director

Age 35
Compensation $6.960M USD
Sex Male

Dr. Sheldon Sloan

Chief Medical Officer

Age 67
Compensation $9.389M USD
Sex Male

Mr. Eric Mcintyre

Investor Relations

Age -
Compensation -
Sex Male

Mr. Jeffrey Albers

Independent Chairman of the Board

Age 53
Compensation $437.6K USD
Sex Male

Mr. Scott Burrows

Chief Financial Officer

Age 48
Compensation $2.207M USD
Sex Male

Ms. Heidy King-Jones

Chief Legal Officer

Corporate Secretary

Age 42
Compensation $6.588M USD
Sex Female

Board of Directors

From the proxy statement filed Apr 10, 2026
Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
2.8 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
Mark McKenna
46 2024
2 years
 Not independent None stated Apogee Therapeutics, Inc. (Nasdaq: APGE) $288,675
Cameron Turtle
CEO
 36 2023
3 years
 Not independent None stated Damora Therapeutics, Inc. (Nasdaq: DMRA) Paid as CEO
Laurie Stelzer
58 2023
3 years
 Independent None stated MBX Biosciences, Inc. (Nasdaq: MBX) $313,675
Jeffrey Albers
54 2023
3 years
 Independent None stated Kymera Therapeutics, Inc. (Nasdaq: KYMR) $348,675
Tomas Kiselak
39 2023
3 years
 Independent None stated Viridian Therapeutics, Inc. (Nasdaq: VRDN) $296,175
Peter Harwin
40 2023
3 years
 Independent None stated Cogent Biosciences, Inc. (Nasdaq: COGT) $293,675
Michael Henderson
36 2023
3 years
 Independent None stated Apogee Therapeutics, Inc. (Nasdaq: APGE) $298,675
Sandra Milligan
62 2024
2 years
 Independent None stated Gossamer Bio, Inc. (Nasdaq: GOSS) $306,175

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 10, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans